Bicara Therapeutics

Bicara Therapeutics is a U.S.-based biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. With approximately 51 employees, the company is led by a experienced team and is dedicated to improving the lives of people living with cancer through the advancement of its lead program, ficerafusp alfa, a first-in-class dual-action antibody targeting EGFR and TGF-β.